Day One – Tuesday February 7th 2012

last modified: 13 February '12

Please enable javascript to see more information on speakers

8am

Registration and refreshments

9am

Chair's Opening Discussion: Clinical Outsourcing: How Do We Overcome Challenges and Ensure the Success of Our Outsourcing Strategy?

Mr Trevor Jones

Professor Jones is a Director of Allergan Inc (USA) and R&D Director of Sigma-Tau S.p.A (Italy).He is Chairman of the UK stem cell biotech company ReNeuron plc , the International CRO Synexus Ltd, a member of the Boards of NextPharma Technologies ...

› Mr Trevor Jones, Former Director-General, ABPI

INSIGHTS INTO KEY OUTSOURCING STRATEGIES

9.30am

Keynote Panel Discussion: clinical outsourcing drivers, issues and solutions

Paula Gildert

Paula is Head of Development Strategic Sourcing , Novartis Pharma, formerly Head R&D Procurement, AstraZeneca and is Fellow and Vice President of the Chartered Institute of Purchasing and Supply. She is responsible for driving value in all...

more..

Finnuala Lonsdale at Clinical Outsourcing World Europe

David Kim

David Kim heads the Vendor Strategy and Management group within Merck & Co. He oversees his teams in all aspects of outsourcing activities which includes alliance management, vendor qualification, study level vendor management, vendor payments, and...

more..

Dr Jeffrey Kasher

Jeffrey S. Kasher, Ph.D., was named vice president and chief operating officer, global clinical development for Eli Lilly and Company in February 2007. He received a bachelor of science degree in chemistry from Franklin & Marshall College...

more..

• Can outsourcing improve efficiency? Is outsourcing a good way to deal with reduced growth and profitability?
• The evolution of outsourcing from tactical to strategic partnerships
• Is the M&A consolidation seen in the pharma and CRO industry impacting clinical outsourcing?
• Pharma 2025: what does the future hold?

› Paula Gildert, Head Strategic Sourcing Development, Novartis Pharma AG
› Finnuala Lonsdale, Global Director, Astrazeneca
› David Kim, Head Vendor Strategy and Management, Merck
› Dr Jeffrey Kasher, Vice President, Eli Lilly and Company

10.30am

Speed networking followed by morning refreshments

CLINICAL OUTSOURCING IN THE REAL WORLD

11.30am

Case study: Strengthening Strategic Partnerships

Dr Jeffrey Kasher

more..

• Forming a strategic partnership is easy, continuously strengthening it is hard
• Framework for a healthy strategic partnership
• Lessons learned and opportunities

› Dr Jeffrey Kasher, Vice President, Eli Lilly and Company

12pm

Case study: The evolution of FSP models: experience of two iterations in a big pharma company

Dennis Joseph

Dennis gained a PhD in Pharmacology before joining the industry as a CRA and held clinical research operational and management roles of increasing responsibility in several pharmaceutical companies and a CRO before joining Pfizer UK as Head of...

more..

• Why FSP?
• Our first experience, how was it for you?
• Evolutionary pressures and the second iteration
• Success factors and other learnings
• Third time lucky?

› Dennis Joseph, Area Head, Clinical Operations (Developed Markets Europe, Korea, Australia) Pfizer Worldwide Research and Development, Pfizer

12.30pm

Case study: The move from tactical to strategic outsourcing

Estrella Garcia

Estrella began her ‘scientific odyssey’ at the University of Navarra, Spain, where she gained a PhD in Genetic Toxicology. Following this, Estrella held at post-doctoral position at ICI (now Astra Zeneca) in Macclesfield, UK. At ICI Estrella’s...

more..

• Why a change in the paradigm was needed
• How Almirall faced the challenge
• Managing the new scenario & outcomes